Practitioner's Docket No. 2000DE133



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Martin SCHMIDT, et al.

RECEIVED

APR 2 6 2002

TECH CENTER 1600/2900

Application No.: 10/001,777

Group No.: 1624

Filed: October 24, 2001

MIXED CRYSTALS OF BENZIMIDAZOLONEDIOXAZINE COMPOUNDS

Assistant Commissioner for Patent Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is mandatory;

TECLION. TECH CENTER 1600/2900 Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address" Mailing Label No. (mandatory)

TRANSMISSION

[]

transmitted by facsimile to the Patent and Trademark Office (703) []

Date: 3-20-2002

(type or print name of person cerlifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).

"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Applicant: Martin SCHMIDT, et al. Serial No. 10/001,777 Page 2

Dear Sir:

4 14 m

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1.	\boxtimes	Enclosures accompanying this information Disclosure Statement are:
		1a. 🛛 Form PTO-1449.
		1b. Copies of Information Disclosure Statement citations.
		1c. EPO Search Report
2.		This Information Disclosure Statement is filed under 37 CFR §1.97(b) with
		the filing of the U.S. patent application. Accordingly, no fee or §1.97(e)
		Statement is required.
3.	\boxtimes	This Information Disclosure Statement is filed under 37 CFR §1.97(b)
		before the latter of three months after the U.S. patent application filing
		date or the first Office Action on the merits. Accordingly, no fee or
		§1.97(e) Statement is required.
4.		This Information Disclosure Statement is filed under 37 CFR §1.97(c) after
		the first Office Action on the merits, but before a Final Office Action or a
		Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in
		accordance with 37 CFR §1.97(c) is to be charged to Deposit Account
		No. 03-2060.

Applicant: Martin SCHMIDT, et al. Serial No. 10/001,777 Page 3

5.	This Information Disclosure Statement is filed under 37 CFR §1.97(e) in
	that each item of information contained in the information disclosure
	statement was cited in a communication from a foreign patent office in a
	counterpart foreign application not more than three months prior to the
	filing of the information disclosure statement. Accordingly, no fee is
	required.

Respectfully submitted,

Anthony A. Bisulca Registration No. 40,913

Clariant Corporation Industrial Property Department 4331 Chesapeake Drive Charlotte, North Carolina 28216 Telephone: 704/395-6701

Facsimile: 704/395-6727